A Simple 3D Cell Culture Method for Studying the Interactions between Human Mesenchymal Stromal/Stem Cells and Patients Derived Glioblastoma.

3D co-cultures glioblastoma and mesenchymal stromal cells

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
18 Feb 2023
Historique:
received: 18 01 2023
revised: 09 02 2023
accepted: 16 02 2023
entrez: 25 2 2023
pubmed: 26 2 2023
medline: 26 2 2023
Statut: epublish

Résumé

We have developed a 3D biosphere model using patient-derived cells (PDCs) from glioblastoma (GBM), the major form of primary brain tumors in adult, plus cancer-activated fibroblasts (CAFs), obtained by culturing mesenchymal stem cells with GBM conditioned media. The effect of MSC/CAFs on the proliferation, cell-cell interactions, and response to treatment of PDCs was evaluated. Proliferation in the presence of CAFs was statistically lower but the spheroids formed within the 3D-biosphere were larger. A treatment for 5 days with Temozolomide (TMZ) and irradiation, the standard therapy for GBM, had a marked effect on cell number in monocultures compared to co-cultures and influenced cancer stem cells composition, similar to that observed in GBM patients. Mathematical analyses of spheroids growth and morphology confirm the similarity with GBM patients. We, thus, provide a simple and reproducible method to obtain 3D cultures from patient-derived biopsies and co-cultures with MSC with a near 100% success. This method provides the basis for relevant in vitro functional models for a better comprehension of the role of tumor microenvironment and, for precision and/or personalized medicine, potentially to predict the response to treatments for each GBM patient.

Identifiants

pubmed: 36831643
pii: cancers15041304
doi: 10.3390/cancers15041304
pmc: PMC9954562
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Acta Neuropathol. 2020 Dec;140(6):919-949
pubmed: 33009951
Front Oncol. 2022 Jul 07;12:891543
pubmed: 35875065
Oncotarget. 2015 Mar 30;6(9):6840-9
pubmed: 25749386
Cancer Discov. 2020 Jul;10(7):964-979
pubmed: 32253265
Radiology. 2018 Jul;288(1):218-225
pubmed: 29924716
Cancers (Basel). 2022 Oct 26;14(21):
pubmed: 36358676
Am J Cancer Res. 2021 Aug 15;11(8):3742-3754
pubmed: 34522446
Brain Pathol. 2009 Oct;19(4):573-85
pubmed: 18662234
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
J Transl Med. 2017 Feb 9;15(1):27
pubmed: 28183348
Ann Oncol. 2017 Jul 1;28(7):1448-1456
pubmed: 28407030
Cell Biosci. 2022 Sep 11;12(1):155
pubmed: 36089610
Sci Rep. 2017 Jul 4;7(1):4575
pubmed: 28676662
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Biomaterials. 2010 Aug;31(22):5903-10
pubmed: 20417555
J Med Imaging (Bellingham). 2015 Apr;2(2):024503
pubmed: 26158107
Oncogenesis. 2020 Feb 5;9(2):11
pubmed: 32024816
Cancer Res. 2009 May 15;69(10):4167-74
pubmed: 19435897
Drug Discov Today. 2023 Feb;28(2):103426
pubmed: 36332834
Stem Cells. 2013 Jun;31(6):1075-85
pubmed: 23401361
Cancers (Basel). 2022 Feb 09;14(4):
pubmed: 35205617
Cancers (Basel). 2022 Oct 31;14(21):
pubmed: 36358795
Cancer Cell. 2018 May 14;33(5):874-889.e7
pubmed: 29681511
Cancer Med. 2020 Jan;9(1):350-360
pubmed: 31746135
Nature. 2004 Nov 18;432(7015):396-401
pubmed: 15549107
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Cancers (Basel). 2020 Sep 24;12(10):
pubmed: 32987868
J Control Release. 2021 Mar 10;331:85-102
pubmed: 33388341
Cancers (Basel). 2022 Jun 30;14(13):
pubmed: 35804976
Cancer Cell. 2013 Sep 9;24(3):331-46
pubmed: 23993863
Oncotarget. 2015 Mar 20;6(8):6267-80
pubmed: 25749043
Mitochondrion. 2020 Nov;55:154-163
pubmed: 33045388
Biomaterials. 2014 Mar;35(8):2454-61
pubmed: 24388382
J Transl Med. 2013 Jan 31;11:28
pubmed: 23369187
Cells. 2021 May 10;10(5):
pubmed: 34068501
Biochem Biophys Res Commun. 2020 Nov 26;533(1):139-147
pubmed: 32943183
Regen Ther. 2021 Dec 10;18:516-522
pubmed: 34977285

Auteurs

Lisa Oliver (L)

Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, CRCI2NA, UMR1307, Nantes Université INSERM, 44007 Nantes, France.
Centre Hospitalier-Universitaire (CHU) de Nantes, 44007 Nantes, France.

Arturo Álvarez-Arenas (A)

Department of Mathematics, MOLAB-Mathematical Oncology Laboratory, University of Castilla-La Mancha, 13071 Ciudad Real, Spain.

Céline Salaud (C)

Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, CRCI2NA, UMR1307, Nantes Université INSERM, 44007 Nantes, France.
Centre Hospitalier-Universitaire (CHU) de Nantes, 44007 Nantes, France.

Juan Jiménez-Sanchez (J)

Department of Mathematics, MOLAB-Mathematical Oncology Laboratory, University of Castilla-La Mancha, 13071 Ciudad Real, Spain.

Gabriel F Calvo (GF)

Department of Mathematics, MOLAB-Mathematical Oncology Laboratory, University of Castilla-La Mancha, 13071 Ciudad Real, Spain.

Juan Belmonte-Beitia (J)

Department of Mathematics, MOLAB-Mathematical Oncology Laboratory, University of Castilla-La Mancha, 13071 Ciudad Real, Spain.

Stephanie Blandin (S)

Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, CRCI2NA, UMR1307, Nantes Université INSERM, 44007 Nantes, France.
Micropicell Facility-INSERM UMS 016, CNRS 3556, Structure Fédérative de Recherche François Bonamy, 44007 Nantes, France.

Luciano Vidal (L)

Institut de Recherche en Génie Civil et Mécanique CNRS-UMR6183, Ecole Centrale de Nantes, Nantes Université, 44300 Nantes, France.

Victor Pérez (V)

Department of Mathematics, MOLAB-Mathematical Oncology Laboratory, University of Castilla-La Mancha, 13071 Ciudad Real, Spain.

Dominique Heymann (D)

Unité en Sciences Biologiques et Biotechnologies, US2B, Nantes Université, CNRS, UMR 6286, US2B, 44322 Nantes, France.
Institut de Cancérologie de l'Ouest, 44805 Saint-Herblain, France.

François M Vallette (FM)

Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, CRCI2NA, UMR1307, Nantes Université INSERM, 44007 Nantes, France.
Institut de Cancérologie de l'Ouest, 44805 Saint-Herblain, France.

Classifications MeSH